A detailed history of Susquehanna Fundamental Investments, LLC transactions in Insmed Inc stock. As of the latest transaction made, Susquehanna Fundamental Investments, LLC holds 270,960 shares of INSM stock, worth $19.3 Million. This represents 0.42% of its overall portfolio holdings.

Number of Shares
270,960
Previous 166,409 62.83%
Holding current value
$19.3 Million
Previous $4.51 Billion 302.12%
% of portfolio
0.42%
Previous 0.21%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

BUY
$22.0 - $69.71 $2.3 Million - $7.29 Million
104,551 Added 62.83%
270,960 $18.2 Billion
Q1 2024

May 07, 2024

BUY
$25.72 - $29.94 $4.28 Million - $4.98 Million
166,409 New
166,409 $4.51 Billion
Q1 2023

May 16, 2023

SELL
$16.26 - $21.73 $325,671 - $435,230
-20,029 Reduced 23.13%
66,573 $1.14 Million
Q4 2022

Feb 14, 2023

BUY
$16.98 - $23.15 $959,658 - $1.31 Million
56,517 Added 187.86%
86,602 $1.73 Million
Q3 2022

Nov 14, 2022

SELL
$20.88 - $28.21 $749,299 - $1.01 Million
-35,886 Reduced 54.4%
30,085 $648,000
Q1 2022

May 16, 2022

BUY
$20.42 - $28.13 $657,217 - $905,364
32,185 Added 95.26%
65,971 $1.55 Million
Q4 2021

Feb 14, 2022

SELL
$25.89 - $33.45 $47,715 - $61,648
-1,843 Reduced 5.17%
33,786 $920,000
Q3 2021

Nov 15, 2021

BUY
$22.46 - $29.47 $95,926 - $125,866
4,271 Added 13.62%
35,629 $981,000
Q2 2021

Aug 11, 2021

BUY
$24.17 - $36.01 $25,088 - $37,378
1,038 Added 3.42%
31,358 $892,000
Q1 2021

May 17, 2021

BUY
$32.28 - $44.3 $368,637 - $505,905
11,420 Added 60.42%
30,320 $1.03 Million
Q3 2020

Nov 16, 2020

BUY
$26.0 - $34.5 $28,600 - $37,950
1,100 Added 6.18%
18,900 $607,000
Q2 2020

Aug 14, 2020

BUY
$14.11 - $29.42 $251,158 - $523,676
17,800 New
17,800 $490,000

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $9.65B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Susquehanna Fundamental Investments, LLC Portfolio

Follow Susquehanna Fundamental Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.